CD8A and neoplasm: VV-IL-2 significantly reduced the tumor burden and improved the survival rate of malignant pleural disease mice, had no significant systemic toxicities compared with VV-YFP, and led to an increase in tumor-infiltrating lymphocytes, particularly CD8+T cells (64).